RT Journal Article
SR Electronic
T1 Prescription of Inhaled corticosteroid in non-cystic fibrosis bronchiectasis:a solution or a problem
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1280
DO 10.1183/13993003.congress-2020.1280
VO 56
IS suppl 64
A1 Bouchareb, soumaya
A1 Touil, Imen
A1 Keskes, Nadia
A1 Ben Rhouma, Chaima
A1 Nemsi, Ella
A1 Romdhane, Raja
A1 Knani, Jalel
A1 Boussoffara, Leila
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/1280.abstract
AB Introduction: The use of inhaled corticosteroids (ICS) would be potentially effective in reducing symptoms and the number of exacerbations in non-cystic fibrosis (N-CF) bronchiectasis.Aims: To evaluate the efficacy and safety of ICS in adults with N-CF bronchiectasis.Methods: Retrospective study including 125patients with N-CF bronchiectasis in stable condition. These patients were divided in two groups: the first group (G1) consists of 70 patients who received ICS and the second group (G2) consists of 55 patients who did not receive ICS.Results: We recruited 125 patients in this study. In the G1, the number of patients hospitalized for acute exacerbation and the number of hospitalizations in the intensive care unit were higher (p <0.05). Also, the number of re-hospitalization in the year following the prescription of ICS was significantly higher in G1(p=0.013). In fact, the average hospitalization rate increased from 0.7 ± 1.04 to 1.34 ±1.66 after ICS therapy. Respiratory function was clearly improved after ICS therapy, in fact the mean FEV increased from 1.38 to 4.62 l/min. The bacteriological investigation revealed a bronchial infection with Pseudomonas Aeroginosa in 8 patients undergoing inhaled corticosteroid therapy, whereas it was only 2 patients in G2 but without a statistically significant difference. The biological inflammatory syndrome was more evident in the G1 (p >0.05).In G1, fifteen patients (21.4%) received oxygen therapy and / or non-invasive ventilation at home versus one patient in G2 (p = 0.17).The number of deaths was greater in the G1 (p = 0.17).Conclusion: ICS can contribute to the improvement of lung function in patientswithnonN-CF bronchiectasis. This benefit remains controversial despite the presence of chronic airway inflammationFootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1280.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).